Summary & Overview
HCPCS G2070: Buprenorphine Implant Medication-Assisted Treatment, Weekly Bundle
HCPCS Level II code G2070 designates a weekly bundled medication assisted treatment (MAT) service for buprenorphine implant insertion delivered by a Medicare-enrolled opioid treatment program. The bundle covers the insertion-related dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing when performed. This code clarifies billing for integrated MAT services that combine pharmacologic and behavioral components under a weekly reimbursement construct.
Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The code is nationally relevant as payers and providers continue to align on coverage and payment for office- and clinic-based MAT modalities that emphasize both medication delivery and behavioral health supports.
Readers will gain a concise overview of the service represented by G2070, payer coverage context, and the clinical setting where the code is typically used. The publication also summarizes benchmark considerations, recent policy updates affecting bundled MAT services for buprenorphine implants, and clinical context for integrated counseling and toxicology components. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G2070 describes medication assisted treatment for buprenorphine implant insertion provided by a Medicare-enrolled opioid treatment program. The code represents a weekly bundled service that includes dispensing and/or administration of the buprenorphine implant, substance use counseling, individual and group therapy, and toxicology testing if performed.
Service type: Medication assisted treatment (buprenorphine implant insertion), weekly bundled services
Typical site of service: Opioid treatment program (OTP) enrolled with Medicare; outpatient substance use treatment setting
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient with moderate-to-severe opioid use disorder presents to a Medicare-enrolled opioid treatment program for placement of a subcutaneous buprenorphine implant. The program schedules a bundled weekly service that includes insertion of the implant, on-site dispensing/administration of medication as needed during the bundle, individual and group substance use counseling, and toxicology testing when performed. The clinical workflow begins with an intake assessment (history, medication reconciliation, consent), pre-procedure evaluation (vital signs, brief focused physical exam, allergy check), and placement of the buprenorphine implant under local anesthesia by an authorized clinician. Post-procedure observation is performed for a short period, with counseling delivered during the same visit or as scheduled group sessions during the bundle week. Point-of-care urine drug testing or laboratory toxicology is performed as clinically indicated. Documentation includes signed consent, implant lot and expiration, insertion site, any complications, counseling notes, toxicology results, and weekly bundle services rendered. Typical site of service is an opioid treatment program clinic or ambulatory behavioral health facility with resources to administer medications and provide counseling; insertion may also occur in outpatient surgical or office-based procedural settings affiliated with the program.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or complexity of the implant insertion or bundled services substantially exceeds usual. |